Theriva Biologics Inc.

Theriva Biologics Inc. is a biopharmaceutical company focused on the development of live, attenuated bacterium-based products for cancer and other diseases. The company's primary aim is to advance the use of oncolytic therapies that leverage bacterial vectors to target and destroy cancer cells selectively, potentially enhancing the efficacy of existing cancer treatments. Its innovative approach seeks to exploit the natural tumor-homing capabilities of genetically engineered bacteria, providing a novel method to deliver therapeutic payloads directly into cancerous tissues. This aligns Theriva Biologics with the broader biopharmaceutical industry trend towards personalized and precision medicine. By engaging in the research and development of such transformative therapeutics, Theriva Biologics plays a significant role in pioneering efforts toward novel cancer treatment paradigms, affecting a wide range of sectors from oncology to microbiome research.